What started as a conversation, in a bar, written on a napkin in 1976, between biochemist Dr. Herbert W. Boyer and investor Robert A. […]
After 50 years of biotech, can AI help answer the next impossible question? Read More »
What will it take to build a stronger, more resilient U.S. life sciences industry? In a June 23 fireside chat at the 2026 BIO
BIO 2026: Gov. Tina Kotek on Oregon’s thriving bioscience sector Read More »
Gary Sinise, Marcus Freeman, and BIO President & CEO John F. Crowley discussed leadership, resilience, and purpose at BIO 2026, drawing lessons from military
BIO 2026: Gary Sinise, Marcus Freeman on leadership, service, and resilience Read More »
Industry, academic, and policy leaders at BIO 2026 discussed how federal research funding, private investment, and public-private partnerships can strengthen the U.S. biopharma ecosystem
From drug discovery to target identification, biotech leaders explored where AI is delivering results today, why data quality matters, and how companies can successfully
BIO 2026: Where AI is delivering – and where biotech must go next Read More »
The Reagan-Udall Foundation for the FDA just released a new report on strengthening early-stage drug development in the United States. The report reflects insights
New report details how U.S. can maintain biotech competitiveness Read More »
When BIO President & CEO John F. Crowley met INDY NXT racer James Roe at a Notre Dame game, something clicked. It wasn’t a
Patient advocacy drives innovation: James Roe’s asthma story comes to BIO 2026 Read More »
At some point in our lives, many of us will find ourselves in a health fight we didn’t expect. A diagnosis. A test result.
A year after a congressional commission urged strategic action to prevent China from replacing America as the world leader in biotechnology, we still have
BIO CEO hails congressional report on threat of China dominating biotech Read More »
Reauthorization of federal seed funding, a top priority for BIO’s work with Congress, passed the House with hefty bipartisan support on March 17 and
SBIR reauthorization, a top BIO priority, is passed by Congress Read More »
